• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Immunologic mediators profile in COVID-19 convalescence

tetano

Editor, Senior Moderator
Sci Rep


. 2024 Sep 9;14(1):20930.
doi: 10.1038/s41598-024-71419-x. Immunologic mediators profile in COVID-19 convalescence

Alexander Leonardo Silva-Junior[SUP] 1 2 [/SUP], Lucas Silva Oliveira[SUP] 1 2 [/SUP], Stephanny Dias[SUP] 2 3 [/SUP], Thaina Cristina Cardoso Costa[SUP] 2 [/SUP], Lilyane Amorim Xabregas[SUP] 2 [/SUP], Fabíola Silva Alves-Hanna[SUP] 2 4 [/SUP], Cláudia Maria Moura Abrahim[SUP] 2 [/SUP], Walter Luiz Lima Neves[SUP] 2 [/SUP], Myuki Alfaia Esashika Crispim[SUP] 2 [/SUP], Diana Mota Toro[SUP] 4 [/SUP], Pedro Vieira Silva-Neto[SUP] 4 [/SUP], Danielle Costa Marques Aponte[SUP] 5 [/SUP], Tatiana Campos Oliveira[SUP] 5 [/SUP], Maria Carmo Costa Silva[SUP] 6 [/SUP], Miharu Maguinoria Matsuura Matos[SUP] 5 [/SUP], Maria Perpétuo Socorro Sampaio Carvalho[SUP] 2 [/SUP], Andrea Monteiro Tarragô[SUP] 2 3 6 [/SUP], Nelson Abrahim Fraiji[SUP] 2 [/SUP], Lúcia Helena Faccioli[SUP] 7 [/SUP], Carlos Artério Sorgi[SUP] 4 8 [/SUP], Ester Cerdeira Sabino[SUP] 9 [/SUP], Andrea Teixeira-Carvalho[SUP] 10 [/SUP], Olindo Assis Martins-Filho[SUP] 10 [/SUP], Allyson Guimarães Costa[SUP] 11 12 13 14 [/SUP], Adriana Malheiro[SUP] 15 16 17 18 19 [/SUP]



Affiliations
Abstract

SARS-CoV-2 caused the pandemic situation experienced since the beginning of 2020, and many countries faced the rapid spread and severe form of the disease. Mechanisms of interaction between the virus and the host were observed during acute phase, but few data are available when related to immunity dynamics in convalescents. We conducted a longitudinal study, with 51 healthy donors and 62 COVID-19 convalescent patients, which these had a 2-month follow-up after symptoms recovery. Venous blood sample was obtained from all participants to measure blood count, subpopulations of monocytes, lymphocytes, natural killer cells and dendritic cells. Serum was used to measure cytokines, chemokines, growth factors, anti-N IgG and anti-S IgG/IgM antibodies. Statistic was performed by Kruskal-Wallis test, and linear regression with days post symptoms and antibody titers. All analysis had confidence interval of 95%. Less than 35% of convalescents were anti-S IgM+, while more than 80% were IgG+ in D30. Anti-N IgG decreased along time, with loss of seroreactivity of 13%. Eosinophil count played a distinct role on both antibodies during all study, and the convalescence was orchestrated by higher neutrophil-to-lymphocyte ratio and IL-15, but initial stages were marked by increase in myeloid DCs, B1 lymphocytes, inflammatory and patrolling monocytes, G-CSF and IL-2. Later convalescence seemed to change to cytotoxicity mediated by T lymphocytes, plasmacytoid DCs, VEGF, IL-9 and CXCL10. Anti-S IgG antibodies showed the longest perseverance and may be a better option for diagnosis. The inflammatory pattern is yet present on initial stage of convalescence, but quickly shifts to a reparative dynamic. Meanwhile eosinophils seem to play a role on anti-N levels in convalescence, although may not be the major causative agent. We must highlight the importance of immunological markers on acute clinical outcomes, but their comprehension to potentialize adaptive system must be explored to improve immunizations and further preventive policies.

Keywords: Antibody; Brazil; Immune hallmarks; Severe acute respiratory syndrome (SARS).

 
Back
Top Bottom